SCHEMBL16631249

SCHEMBL16631249

O=c1cc(F)c([C@@H]2O[C@H](CO)C(O)[C@@H]2F)c(F)[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDA P32320 1/20 0.38
SLC28A1 O00337 1/20 0.35
SLC28A2 O43868 1/20 0.35
SLC29A1 Q99808 1/20 0.35
SLC28A3 Q9HAS3 1/20 0.35
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
SLC5A2 P31639 2/20 0.33
SYNJ2 O15056 1/20 0.33
B4GALT1 P15291 1/20 0.33
P2RY14 Q15391 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GMNN O75496 1/20 0.33
MAPT P10636 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
NFKB1 P19838 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631823 0.89 SYNJ2 (0.42) SLC28A1SLC28A2SLC29A1SLC28A3LMNA
SCHEMBL16631251 0.87 CDA (0.37) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL16631175 0.84 CDA (0.35) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL16631821 0.83 TNF (0.37) LMNASLC5A2SYNJ2B4GALT1P2RY14
SCHEMBL18079916 0.82 CDA (0.34) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL16631525 0.77 SLC28A1 (0.41) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL18079976 0.77 P2RY2 (0.49) B4GALT1P2RY14
SCHEMBL16631826 0.76 SYNJ2 (0.46) LMNASMN1; SMN2SLC5A2SYNJ2KDM4E
SCHEMBL16631270 0.76 CDA (0.38) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL16631160 0.75 CDA (0.35) CDALMNASMN1; SMN2SYNJ2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 CDA 200/4885SLC28A1 302/4885SLC28A2 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.